NEW YORK (GenomeWeb News) – KineMed said today that it has entered an agreement with Amgen to apply its mass spec-based Dynamic Proteomics platform to the study of brain protein homeostasis in neurodegenerative disease.

Amgen will use the data generated by the platform to track synthesis and clearance rates of pathogenic brain proteins that drive neurodegeneration.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.